Canada
· Delayed Price · Currency is CAD RAMM Pharma Statistics
Total Valuation
RAMM Pharma has a market cap or net worth of CAD 2.39 million. The enterprise value is -59,554.
| Market Cap | 2.39M |
| Enterprise Value | -59,554 |
Important Dates
The next estimated earnings date is Friday, September 27, 2024.
| Earnings Date | Sep 27, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
RAMM Pharma has 119.39 million shares outstanding. The number of shares has decreased by -2.10% in one year.
| Shares Outstanding | 119.39M |
| Shares Change (YoY) | -2.10% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 26.93% |
| Owned by Institutions (%) | 0.92% |
| Float | 87.24M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.52 |
| PB Ratio | 0.09 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.01 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 0.01 |
Financial Position
The company has a current ratio of 3.28, with a Debt / Equity ratio of 1.14.
| Current Ratio | 3.28 |
| Quick Ratio | 2.01 |
| Debt / Equity | 1.14 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.07 |
| Interest Coverage | -172.74 |
Financial Efficiency
Return on equity (ROE) is -29.14% and return on invested capital (ROIC) is -14.31%.
| Return on Equity (ROE) | -29.14% |
| Return on Assets (ROA) | -13.36% |
| Return on Capital (ROIC) | -14.31% |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | 0.14 |
| Inventory Turnover | 1.29 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -80.00% in the last 52 weeks. The beta is -0.27, so RAMM Pharma's price volatility has been lower than the market average.
| Beta (5Y) | -0.27 |
| 52-Week Price Change | -80.00% |
| 50-Day Moving Average | 0.02 |
| 200-Day Moving Average | 0.03 |
| Relative Strength Index (RSI) | 63.28 |
| Average Volume (20 Days) | 5,700 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, RAMM Pharma had revenue of CAD 4.59 million and -8.92 million in losses. Loss per share was -0.07.
| Revenue | 4.59M |
| Gross Profit | 241,089 |
| Operating Income | -7.11M |
| Pretax Income | -8.91M |
| Net Income | -8.92M |
| EBITDA | -6.32M |
| EBIT | -7.11M |
| Loss Per Share | -0.07 |
Balance Sheet
The company has 2.75 million in cash and 299,652 in debt, giving a net cash position of 2.45 million or 0.02 per share.
| Cash & Cash Equivalents | 2.75M |
| Total Debt | 299,652 |
| Net Cash | 2.45M |
| Net Cash Per Share | 0.02 |
| Equity (Book Value) | 26.35M |
| Book Value Per Share | 0.22 |
| Working Capital | 5.30M |
Cash Flow
In the last 12 months, operating cash flow was -4.27 million and capital expenditures -65,500, giving a free cash flow of -4.33 million.
| Operating Cash Flow | -4.27M |
| Capital Expenditures | -65,500 |
| Free Cash Flow | -4.33M |
| FCF Per Share | -0.04 |
Margins
Gross margin is 5.25%, with operating and profit margins of -154.81% and -194.21%.
| Gross Margin | 5.25% |
| Operating Margin | -154.81% |
| Pretax Margin | -193.99% |
| Profit Margin | -194.21% |
| EBITDA Margin | -137.65% |
| EBIT Margin | -154.81% |
| FCF Margin | -94.36% |
Dividends & Yields
RAMM Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 2.10% |
| Shareholder Yield | 2.10% |
| Earnings Yield | -372.48% |
| FCF Yield | -181.45% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
RAMM Pharma has an Altman Z-Score of -1.31. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.31 |
| Piotroski F-Score | n/a |